TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16361624

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg orally once a day
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg orally once a day
Number of subjects: 115
Study: 11991766

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) 3 times per week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham stimulation (Control group)
Number of subjects: 27
Study: 10798055

Group type: COMPARATOR
Intervention: Prednisolone (daily 60 mg/m2 for 4 weeks, then 45, 30, 20, 10, 5 mg/m2 on alternate days for 4 weeks)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High dose methylprednisolone (HDMP) (30 mg/kg/d for 3 days, 20 mg/kg/d for 4 days, 10 mg/kg/d for 1 week)
Number of subjects: 15
Study: 8576660

Group type: EXPERIMENTAL
Intervention: Intravenous PCA (Patient-Controlled Analgesia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 0

Group type: COMPARATOR
Intervention: I.M. method (Intramuscular)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCA group
Number of subjects: 0
Study: 2127674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg nicergoline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30 mg nicergoline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 60 mg nicergoline
Number of subjects: 16
Study: 7000228

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no metronidazole)
Number of subjects: 116
Study: 31870091

Group type: EXPERIMENTAL
Intervention: Tobacco free health education intervention (40 min session once a week for 3 weeks, plus take home brochures)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional standard health education (once)
Number of subjects: 250
Study: 27885536

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG) after removal of adjustable gastric banding (LAGB)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 109
Study: 27509187

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 3000 IU/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 40
Study: 24809921

Group type: EXPERIMENTAL
Intervention: Trimetazidine treatment group (TG)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Trimetazidine treatment
Number of subjects: 768

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 768
Study: 21968279

Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture (TA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sham Acupuncture (SA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Adrenocorticotropic hormone stimulation
Number of subjects: 33
Study: 19648224

Group type: EXPERIMENTAL
Intervention: 200 mg Modafinil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17504903

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg im (first dose), followed by 500 mg im every 6 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Submersion of scrota at 43 C in water for 30 min/d for 6 consecutive days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) plus heat
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) plus oral levonorgestrel (LNG) 250 microg/d
Number of subjects: 72

Group type: COMPARATOR
Intervention: Heat treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) plus LNG
Number of subjects: 72

Group type: COMPARATOR
Intervention: Heat treatment only
Number of subjects: 72
Study: 16243723

Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Vigorous intensity physical activity
Number of subjects: 178
Study: 12495242

Group type: EXPERIMENTAL
Intervention: Self-control feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yoked feedback
Number of subjects: 0
Study: 9653685

Group type: EXPERIMENTAL
Intervention: Joint mobilization and comprehensive treatment (hot packs, active range of motion, physiologic stretching, muscle strengthening, soft tissue mobilization, and patient education)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Joint mobilization and comprehensive treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comprehensive treatment alone
Number of subjects: 14
Study: 7505819

Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP (18.5 MBq or 37 MBq per kg body weight)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP
Number of subjects: 19
Study: 2686575

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 30269562

Group type: EXPERIMENTAL
Intervention: BFR40 and BFR50
Number of subjects: 12

Group type: COMPARATOR
Intervention: HI-RE
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BFR70 and BFR80
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BFR60, BFR70, and BFR80
Number of subjects: 12
Study: 26522708

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks through week 24 and every 8 weeks through week 48.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grid laser at baseline and IAI every 8 weeks after 3 monthly doses from week 24 onward (laser/IAI group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grid laser and IAI (laser/IAI group).
Number of subjects: 0
Study: 25632802

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES) before SEMS placement
Number of subjects: 200

Group type: COMPARATOR
Intervention: No endoscopic sphincterotomy (non-ES) before SEMS placement
Number of subjects: 200
Study: 24029269

Group type: EXPERIMENTAL
Intervention: Nicotinamide 500 mg twice/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21921853

Group type: EXPERIMENTAL
Intervention: Temporal fascia
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Tragus perichondrium
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Tragus cartilage‐perichondrium composite grafts
Number of subjects: 117

Group type: COMPARATOR
Intervention: Small perforation group (all interventions)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Temporalis fascia or perichondrium (for large perforations)
Number of subjects: 117
Study: 18556747

Group type: EXPERIMENTAL
Intervention: Icodextrin-containing PD solutions (Extraneal)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Non-icodextrin-containing PD solutions
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Icodextrin from two independent manufacturers
Number of subjects: 722

Group type: COMPARATOR
Intervention: Control group (non-icodextrin)
Number of subjects: 722
Study: 16979005

Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Pharmacologic Therapy (PT) alone
Number of subjects: 187
Study: 14551366

Group type: EXPERIMENTAL
Intervention: Low-dose spironolactone (25 mg three times/week)
Number of subjects: 35
Study: 11256554

Group type: EXPERIMENTAL
Intervention: Pranlukast (450 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bronchodilators and inhaled steroid (beclomethasone dipropionate; 400 microg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bronchodilators alone
Number of subjects: 30
Study: 9164896

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8171288

Group type: EXPERIMENTAL
Intervention: Activated peroral charcoal (50 g 3 times a day for 8 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal follow-up (Control)
Number of subjects: 19
Study: 3146125

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g single dose at the time of surgery)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 113
Study: 30831453

Group type: EXPERIMENTAL
Intervention: Calorie deprivation for two days
Number of subjects: 23
Study: 28159854

Group type: EXPERIMENTAL
Intervention: Patient Reporting and Action for a Safe Environment (PRASE) intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control wards
Number of subjects: 86
Study: 25335876

Group type: EXPERIMENTAL
Intervention: Triple P seminar series
Number of subjects: 143

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 143
Study: 22752286

Group type: EXPERIMENTAL
Intervention: PEEP = 10 cmH(2)O (PEEP group, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No external PEEP (ZEEP group, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (PEEP and ZEEP)
Number of subjects: 60
Study: 21764711

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3-D conformal radiotherapy (3-DCRT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3-DCRT
Number of subjects: 60
Study: 18585635

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy with maintenance protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy with maintenance treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG maintenance treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SWOG protocol for BCG therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced dose of BCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized approach to BCG therapy
Number of subjects: 0
Study: 17238456

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12623474

Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol orally
Number of subjects: 496

Group type: COMPARATOR
Intervention: 10 IU oxytocin intramuscularly
Number of subjects: 496
Study: 10999784

Group type: EXPERIMENTAL
Intervention: Metyrapone (500 mg every 4 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study: 9081136

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 60 micrograms, intravenous infusion, 5 days a week for 4 weeks, followed by twice a week for 4 weeks
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 31969545

Group type: EXPERIMENTAL
Intervention: Optibond™FL
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Prime&Bond®NT™
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Clearfil™SE Bond
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Xeno®III
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Xeno®V+
Number of subjects: 159

Group type: COMPARATOR
Intervention: Etch‐and‐rinse adhesives (combined performance)
Number of subjects: 159
Study: 30127194

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (100%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Polyol chewing gum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 60
Study: 29231562

Group type: EXPERIMENTAL
Intervention: Needle-knife combined with pseudo-ginseng-cake moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of western medication
Number of subjects: 60
Study: 24405492

Group type: EXPERIMENTAL
Intervention: Threshold suspend (TS) feature, insulin stopped for 2 hours once SG value of ≤70 mg/dL detected
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (basal insulin delivery continued)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Threshold suspend (TS) feature
Number of subjects: 50
Study: 22168429

Group type: EXPERIMENTAL
Intervention: GlideCoach and verbal feedback
Number of subjects: 19

Group type: COMPARATOR
Intervention: Video and verbal feedback
Number of subjects: 19

Group type: COMPARATOR
Intervention: Video feedback
Number of subjects: 19
Study: 19931156

Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg as an intermittent bolus 3 times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pantoprazole (40 mg as an intermittent bolus twice a day)
Number of subjects: 20
Study: 16671978

Group type: EXPERIMENTAL
Intervention: Acupuncture for migraine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control interventions (not specified)
Number of subjects: 0
Study: 15288222

Group type: EXPERIMENTAL
Intervention: 5 mL of 1% lignocaine injected at the 4 and 8 o'clock positions of the vaginal vault
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 5 mL of 1% lignocaine injected at the 4 and 8 o'clock positions of the cervix
Number of subjects: 135

Group type: COMPARATOR
Intervention: No PCB
Number of subjects: 135
Study: 11703890

Group type: EXPERIMENTAL
Intervention: Women's safer sex hierarchy of prevention methods (hierarchy cohort)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Male condom only (MC cohort)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Female condom only (FC cohort)
Number of subjects: 292
Study: 9135288

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 8689733

Group type: EXPERIMENTAL
Intervention: Geristore restoration system after cavity cleaned with 10% NaOCl solution and 3% H2O2 solution (Group G)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Geristore restoration system after cavity applied with Mirage-Bond (Group MG)
Number of subjects: 22
Study: 3583500

Group type: EXPERIMENTAL
Intervention: Esaprazole 900 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Esaprazole 1800 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31038442

Group type: EXPERIMENTAL
Intervention: Figurative art
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Modern art
Number of subjects: 77

Group type: COMPARATOR
Intervention: Museum office (control)
Number of subjects: 77
Study: 28266950

Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexmedetomidine (group RD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine + Tramadol (group RT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ropivacaine (group R)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 26614615

Group type: EXPERIMENTAL
Intervention: User-centred critical care discharge information pack (UCCDIP)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Ad hoc verbal information (control 1)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Booklet published by ICUsteps (control 2)
Number of subjects: 158
Study: 23971455

Group type: EXPERIMENTAL
Intervention: Lesion management application
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual method
Number of subjects: 50
Study: 21926186

Group type: EXPERIMENTAL
Intervention: golimumab 100mg + placebo
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: golimumab 50mg + methotrexate
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: golimumab 100mg + methotrexate
Number of subjects: 1081

Group type: COMPARATOR
Intervention: subcutaneous placebo + methotrexate
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: CRP changes at week 4
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: RAMRIS scores at week 12
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: MRI and clinical/laboratory/radiographic measures
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Changes in MRI and clinical/radiographic measures
Number of subjects: 1081
Study: 18434462

Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 25
Study: 16763968

Group type: EXPERIMENTAL
Intervention: Single-voxel point resolved spectroscopy at 4.0 T in anterior cingulate
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Single-voxel point resolved spectroscopy at 4.0 T in hippocampus
Number of subjects: 53

Group type: COMPARATOR
Intervention: Variability measurements in healthy subjects
Number of subjects: 53

Group type: COMPARATOR
Intervention: Calculations for detecting differences in NAA
Number of subjects: 53
Study: 15343195

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intensive insulin injection therapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 42
Study: 11177203

Group type: EXPERIMENTAL
Intervention: Bicarbonate-rich mineral water (1715 mg bicarbonate/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium potassium citrate
Number of subjects: 0
Study: 9051880

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 0.5 g daily for 2 years
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 8378156

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (50 mg/kg)/promethazine (1 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Meperidine (1 mg/kg)/promethazine (1 mg/kg)
Number of subjects: 24
Study: 2878859

Group type: EXPERIMENTAL
Intervention: Azodisal sodium (1 g/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Azodisal sodium (1 g/day vs 2 g/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Azodisal sodium (2 g/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo or sulphasalazine (2 g/day)
Number of subjects: 18
Study: 30292613

Group type: EXPERIMENTAL
Intervention: Percutaneous access of the common femoral artery (CFA) with a percutaneous closure device
Number of subjects: 274

Group type: COMPARATOR
Intervention: Open surgical access of the CFA
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: MDs only (for percutaneous access)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Percutaneous access
Number of subjects: 274

Group type: COMPARATOR
Intervention: Open surgical access
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Nasal or groin Staphylococcus aureus carriage
Number of subjects: 274
Study: 29348326

Group type: EXPERIMENTAL
Intervention: Programmed histone inheritance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized inheritance of preexisting histones versus newly synthesized histones
Number of subjects: 0
Study: 24215715

Group type: EXPERIMENTAL
Intervention: Locator® attachments
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dolder® bar
Number of subjects: 46
Study: 24377219

Group type: EXPERIMENTAL
Intervention: Warming-promoting needling and target penetrating needling method (WT group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional acupuncture (CA group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medication (M group)
Number of subjects: 90
Study: 21490928

Group type: EXPERIMENTAL
Intervention: Hearing a stranger's voice as feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline condition (hearing their own voice as feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hearing a stranger's voice (illusion present)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hearing a stranger's voice (illusion broken)
Number of subjects: 0
Study: 19922881

Group type: EXPERIMENTAL
Intervention: Fentanyl 50 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl 100 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (0.9% isotonic saline)
Number of subjects: 120
Study: 17074269

Group type: EXPERIMENTAL
Intervention: SmartCare (SC group, n = 13)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Spontaneous Breathing Trials (SBT group, n = 25)
Number of subjects: 38
Study: 14746859

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg, ondansetron 32 mg i.v., dexamethasone 12 mg on day 1, aprepitant 80 mg and dexamethasone 8 mg on days 2-3, dexamethasone 8 mg on day 4
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Standard therapy (ondansetron 32 mg i.v. and dexamethasone 20 mg on day 1, dexamethasone 8 mg b.i.d. on days 2-4)
Number of subjects: 1038
Study: 11762560

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 microg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 1000 microg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 microg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9373703

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8510490

Group type: EXPERIMENTAL
Intervention: 12-month course of alfa interferon therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (untreated cases)
Number of subjects: 61
Study: 3319536

Group type: EXPERIMENTAL
Intervention: 3 g/day GVG
Number of subjects: 75

Group type: COMPARATOR
Intervention: 1.5 g/day GVG
Number of subjects: 75
Study: 31129775

Group type: EXPERIMENTAL
Intervention: Erigo® verticalization
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional neurorehabilitation
Number of subjects: 44
Study: 28705663

Group type: EXPERIMENTAL
Intervention: Alcoholic beer (BAC of 0.03)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-alcoholic beer (placebo)
Number of subjects: 0
Study: 26101276

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 200
Study: 23432812

Group type: EXPERIMENTAL
Intervention: PHiD‐CV co‐administered with DTPa‐HBV‐IPV/Hib
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (DTPa‐HBV‐IPV/Hib alone)
Number of subjects: 300
Study: 20855188

Group type: EXPERIMENTAL
Intervention: NIOX MINO(®) analyser
Number of subjects: 17
Study: 19521297

Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke spinal needle (Group Q)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 25-gauge ballpen spinal needle (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 25-gauge pencil-point spinal needle (Group P)
Number of subjects: 45